Titelbild
Indication Discovery in vivo POC pre-IND Phase I
Orphan Disease
ADA-1
Type 1 Diabetes
Celiac Disease
Multiple Sclerosis
Partnering opportunity

Pipeline

Topas is utilizing its cutting-edge technology platform to develop a pipeline of novel therapies to treat autoimmune diseases, allergies and anti-drug antibodies.

  • Orphan disease: For this indication, there is already extensive knowledge about the related antigen, a validated biomarker and a clear and fast clinical phenotype. Thus, it is an ideal area to demonstrate clinical proof-of-concept for the Topas Particle Conjugates (TPC) technology. The program is currently in confirmatory pre-clinical proof-of-concept studies and is expected to enter the clinic in 2019.
  • ADA-1: Topas is exploring a model system to prove successful projection of its approach towards the prevention of neutralizing antibodies generated against a marketed therapeutic. The program’s initial goal is to achieve pre-clinical proof-of-concept.
  • Type 1 diabetes: This program is being co-developed with Evotec and is initially focused on achieving pre-clinical proof-of-concept. Should this program be successful, it would support the ability of the Topas platform to also regulate cytotoxic CD8+ T-cells. Type 1 diabetes represents an attractive commercial opportunity as there remains a need for treatments that are disease modifying and are more convenient and comfortable for patients, who are often children.
  • Celiac disease: Patients with celiac disease must avoid a wide variety of foods or suffer often severe stomach pain. Gluten is a well-described external antigen, making this a good area of focus for the TPC technology. The initial goal of this program is to achieve pre-clinical proof-of-concept.
  • Multiple sclerosis (MS): Despite significant progress in finding new, more effective treatments for MS, there remains a need to find causative therapies that are more effective, convenient and comfortable for patients. The Topas program comprises a number of TPCs representing several MS antigens. Early pre-clinical results demonstrated that, in an autoimmune encephalomyelitis model (common model to represent MS), all mice were fully protected from developing MS by a one-time injection of an MS-relevant TPC. This program is available for partnering.